TTNP — Titan Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $6.69m
- $0.43m
- $0.18m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.01 | ||
| Price to Tang. Book | 1.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 36.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -109.56% | ||
| Return on Equity | -139.16% | ||
| Operating Margin | -3954.89% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.6 | 4.84 | 1.53 | 0.56 | 0.18 | n/a | n/a | -51.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Directors
- Marc Rubin CHM (66)
- Katherine DeVarney PRE (60)
- Joseph Akers IND (75)
- M. David MacFarlane IND (80)
- James McNab IND (77)
- Scott Smith IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 7th, 1992
- Public Since
- January 18th, 1996
- No. of Shareholders
- 98
- No. of Employees
- 4
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 914,234
- Address
- SUITE 505, 400 OYSTER POINT BLVD, SAN FRANCISCO, 94080
- Web
- https://www.titanpharm.com/
- Phone
- +1 4152444990
- Auditors
- WithumSmith Brown PC
Upcoming Events for TTNP
Similar to TTNP
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Aadi Bioscience
NASDAQ Capital Market
Acasti Pharma
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Aptorum
NASDAQ Capital Market
FAQ
What is the Titan Pharmaceuticals share price?
As of Today at 19:21 UTC, shares in Titan Pharmaceuticals are trading at $7.32. This share price information is delayed by 15 minutes.
How has the Titan Pharmaceuticals share price performed this year?
Shares in Titan Pharmaceuticals last closed at $7.32 and the price had moved by +859.55% over the past 365 days. In terms of relative price strength the Titan Pharmaceuticals share price has outperformed the S&P500 Index by +698.5% over the past year.
What are the analyst and broker recommendations for Titan Pharmaceuticals?
The overall consensus recommendation for Titan Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Titan Pharmaceuticals dividend yield?
Titan Pharmaceuticals does not currently pay a dividend.
Does Titan Pharmaceuticals pay a dividend?
Titan Pharmaceuticals does not currently pay a dividend.
When does Titan Pharmaceuticals next pay dividends?
Titan Pharmaceuticals does not currently pay a dividend.
How do I buy Titan Pharmaceuticals shares?
To buy shares in Titan Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Titan Pharmaceuticals?
As of the previous close price of $7.32, shares in Titan Pharmaceuticals had a market capitalisation of $6.69m.
Where are Titan Pharmaceuticals shares listed?
Here are the trading details for Titan Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TTNP
What kind of share is Titan Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Titan Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Titan Pharmaceuticals share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Titan Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Titan Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +1531.84%.
As of the last closing price of $7.32, shares in Titan Pharmaceuticals were trading +177.7% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Titan Pharmaceuticals PE Ratio?
The Titan Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Titan Pharmaceuticals?
Titan Pharmaceuticals' management team is headed by:
- Marc Rubin - CHM
- Katherine DeVarney - PRE
- Joseph Akers - IND
- M. David MacFarlane - IND
- James McNab - IND
- Scott Smith - IND